Intranasal drug developer Impel NeuroPharma has raised $67.5 million in a Series D financing round led by KKR and Norwest Venture Partners, the company said. Existing investors Vivo Capital, 5AM Ventures and venBio Partners also participated. According to Impel, the funds will be used to accelerate development of its pipeline of drugs based on its Precision Olfactory … [Read more...] about Impel Neuropharma raises over $67 million for development of intranasal products
Business
Shionogi invests in inhaled nitric oxide powder developer Vast Therapeutics
Vast Therapeutics (formerly Novoclem) has announced that Shionogi & Co. was the sole investor in a Series A financing round that will fund pre-clinical and Phase 1 development of the company's dry powder nitric oxide for the treatment of respiratory infections in cystic fibrosis patients, with the expectation of a licensing agreement. The amount of the investment was … [Read more...] about Shionogi invests in inhaled nitric oxide powder developer Vast Therapeutics
Neurelis acquires Aegis Therapeutics
US Pharmaceutical company Neurelis, which recently submitted an NDA for Valtoco diazepam nasal spray, has acquired Aegis Therapeutics and its Intravail transmucosal absorption technology, a component of the Valtoco formulation. In addition to Intravail, Aegis Therapeutics offers two other excipients that can be used in nasal formulations, ProTek and Aegis Hydrogels, … [Read more...] about Neurelis acquires Aegis Therapeutics
Phase 3 trial of VR475 inhalation suspension fails to meet primary endpoint, Vectura discontinues development
Vectura has announced that a Phase 3 study of VR475 budesonide inhalation suspension for the treatment of severe uncontrolled asthma in adult and adolescent patients failed to meet its primary endpoint. As a result, the company said that it would discontinue development of VR475 (formerly known as Favolir), which it acquired when it acquired Activaero in … [Read more...] about Phase 3 trial of VR475 inhalation suspension fails to meet primary endpoint, Vectura discontinues development
InCarda Therapeutics raises $42 million, initiates Phase 2 trial of inhaled flecainide
InCarda Therapeutics has announced the completion of an oversubscribed $42 million Series B financing that will fund a Phase 2 study of InRhythm inhaled flecainide for the treatment of recent-onset paroxysmal atrial fibrillation (PAF). The financing round was led by Sofinnova and HealthCap, both new investors along with Deerfield Management. In 2015, InCarda raised … [Read more...] about InCarda Therapeutics raises $42 million, initiates Phase 2 trial of inhaled flecainide
Vectura to develop generic versions of Ellipta DPIs with Hikma
Vectura and Hikma Pharmaceuticals have announced a deal for development and commercialization of generic versions of GSK's Ellipta dry powder inhalers. Hikma will pay Vectura $15 million up front, $5 million at the start of clinical manufacturing for the first product, up to $75 million in development milestones, a percentage of distributable share of net profit on … [Read more...] about Vectura to develop generic versions of Ellipta DPIs with Hikma
Covis Pharma acquires additional rights to Alvesco, Omnaris, and Zetonna from AstraZeneca
AstraZeneca has announced that Covis Pharma will pay $350 million up front for the rights to market Alvesco ciclesonide MDI and the ciclesonide nasal spray Omnaris and nasal MDI Zetonna outside of the US. The deal also includes up to $21 million in potential payments conditioned on sales over the 4 years beginning in 2019. Covis acquired US rights to Alvesco, Omnaris, … [Read more...] about Covis Pharma acquires additional rights to Alvesco, Omnaris, and Zetonna from AstraZeneca
Receptor Life Sciences raises $29 million
Receptor Life Sciences has raised $29 million for development of several cannabinoid products, the company said. In 2016, MannKind Corporation announced that it had licensed its dry powder inhalation technology to Receptor, which was then newly formed. According to the company, "Receptor’s inhalation technology combines a simple-to-use, breath-powered inhaler … [Read more...] about Receptor Life Sciences raises $29 million
Glenmark opens new manufacturing facility in US
Glenmark Pharmaceuticals has officially opened its first US manufacturing site in Monroe, North Carolina, the company said. The 100,000 sq ft, $100 million facility will eventually produce hundreds of millions of doses in various forms annually, including 25-30 million inhalation ampoules. The site currently employs 168 people, and the Glenmark said that it expects … [Read more...] about Glenmark opens new manufacturing facility in US
GSK opens new Ellipta API manufacturing facility in Scotland
According to the Scottish government, a new manufacturing facility built by GSK in Montrose to produce APIs for its Ellipta dry powder inhalers officially opened on October 22, 2018, with Scottish First Minister Nicola Sturgeon in attendance. Sturgeon commented, “This new facility is testament to GSK’s commitment to Montrose and reinforces the region’s position … [Read more...] about GSK opens new Ellipta API manufacturing facility in Scotland